Loading...
•
Mar 31, 2022
Checkpoint Therapeutics Q1 2022 Earnings Report
Reported first quarter 2022 financial results and recent corporate highlights.
Key Takeaways
Checkpoint Therapeutics announced positive top-line results from the registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma. The company is on track to submit the U.S. Biologics License Application for cosibelimab later this year and is evaluating partnership opportunities for commercialization in Europe and other key territories.
Positive top-line results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma announced in January 2022.
BLA submission expected in 2022.
Evaluating partnership opportunities for the potential commercialization of cosibelimab in Europe and other key territories worldwide.
Focus remains on advancing pipeline of potentially life-saving novel oncology therapies with the goal of expanding patient access globally through a disruptive pricing strategy.
Forward Guidance
Checkpoint Therapeutics is on track to submit the U.S. Biologics License Application (“BLA”) for cosibelimab later this year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...